Enanta Pharmaceuticals, Inc. to Post Q1 2025 Earnings of ($1.15) Per Share, HC Wainwright Forecasts (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Enanta Pharmaceuticals in a report issued on Tuesday, May 7th. HC Wainwright analyst E. Arce expects that the biotechnology company will earn ($1.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.90) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.57) EPS and Q4 2025 earnings at ($1.66) EPS.

Several other brokerages also recently commented on ENTA. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. JPMorgan Chase & Co. cut their price objective on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Thursday, February 8th. Finally, JMP Securities decreased their price objective on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Tuesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Hold” and an average price target of $19.00.

Enanta Pharmaceuticals Stock Up 1.3 %

Shares of ENTA opened at $12.93 on Thursday. The business’s 50-day moving average price is $14.85 and its 200-day moving average price is $12.09. The stock has a market cap of $273.55 million, a PE ratio of -2.07 and a beta of 0.54. Enanta Pharmaceuticals has a twelve month low of $8.08 and a twelve month high of $28.25.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). The company had revenue of $18.00 million during the quarter, compared to the consensus estimate of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its stake in Enanta Pharmaceuticals by 613.6% in the third quarter. Assenagon Asset Management S.A. now owns 631,626 shares of the biotechnology company’s stock worth $7,055,000 after buying an additional 543,111 shares in the last quarter. Jump Financial LLC grew its holdings in shares of Enanta Pharmaceuticals by 41.5% during the 3rd quarter. Jump Financial LLC now owns 56,636 shares of the biotechnology company’s stock valued at $633,000 after purchasing an additional 16,608 shares during the last quarter. Clearstead Advisors LLC bought a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at $57,000. Quantbot Technologies LP lifted its stake in Enanta Pharmaceuticals by 2,300.0% in the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 6,900 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in shares of Enanta Pharmaceuticals during the third quarter valued at about $698,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.